Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
2013714 citationsMarcus Maurer, Karin Rosén et al.New England Journal of Medicineprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Clive Grattan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clive Grattan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clive Grattan more than expected).
This network shows the impact of papers produced by Clive Grattan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clive Grattan. The network helps show where Clive Grattan may publish in the future.
Co-authorship network of co-authors of Clive Grattan
This figure shows the co-authorship network connecting the top 25 collaborators of Clive Grattan.
A scholar is included among the top collaborators of Clive Grattan based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Clive Grattan. Clive Grattan is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Maurer, Marcus, Karsten Weller, Alla Nakonechna, et al.. (2014). The first international study assessing the economic and humanistic burden of refractory chronic spontaneous/idiopathic urticaria: ASSURE-CSU. 69. 122–122.1 indexed citations
4.
Maurer, Marcus, Karin Rosén, Hsin-Ju Hsieh, et al.. (2013). Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. New England Journal of Medicine. 368(10). 924–935.714 indexed citations breakdown →
Lachmann, Helen J., et al.. (2006). The phenotype of patients with cryopyrin-associated periodic syndrome and response to treatment with anti-interleukin 1 (anakinra).. British Journal of Dermatology. 155. 6–7.1 indexed citations
Zuberbier, Torsten, Carsten Bindslev‐Jensen, Giorgio Walter Canonica, et al.. (2006). EAACI/GA2LEN/EDF guideline: Definition, classifikation and diagnosis of urticaria. University of Southern Denmark Research Portal (University of Southern Denmark). 61. 316–320.31 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.